Skip to content
OpenCapital
Get started

Spyre Therapeutics, Inc. SYRE Investments - Gross Unrealized Losses

Investments - Gross Unrealized Losses at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——

Other financials

Income statement

See full
Revenue-—
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-—
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$7.67B+307%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s investments - gross unrealized losses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s investments - gross unrealized losses?
Spyre Therapeutics, Inc. (SYRE) reported investments - gross unrealized losses of $432M in Q1 2026.
How has Spyre Therapeutics, Inc.'s investments - gross unrealized losses changed year-over-year?
Spyre Therapeutics, Inc.'s investments - gross unrealized losses increased by 310.8% year-over-year, from $105.15M to $432M.
What is the long-term trend for Spyre Therapeutics, Inc.'s investments - gross unrealized losses?
Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s investments - gross unrealized losses has grown at a 93.0% compound annual growth rate (CAGR), from $25.17M to $180.96M.